Oyeyemi Adeniran
Urology · Waxahachie, TXNPI 1922779677
Payments from drug & device makers
Across 113 payments — averaging $42.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$1K
- Medtronic$783
- Sumitomo Pharma America, Inc.$684
- Boston Scientific$620
- Antares Pharma, Inc.$324
- Astellas Pharma US Inc$243
- plus $688 from 20 others
What the payments were for
- Travel & lodging$1,51932%
- Food & beverage$3,22568%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 17 | $1,428 |
| Medtronic | 12 | $783 |
| Sumitomo Pharma America, Inc. | 23 | $684 |
| Boston Scientific | 6 | $620 |
| Antares Pharma, Inc. | 12 | $324 |
| Astellas Pharma US Inc | 12 | $243 |
| AbbVie | 3 | $91 |
| Procept Biorobotics Corporation | 3 | $87 |
| 180 Medical, Inc. | 4 | $84 |
| Urovant Sciences Inc | 3 | $78 |
| Convatec Inc. | 3 | $67 |
| Pfizer | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Bayer | 1 | $23 |
| ABC Home Medical Supply, Inc. | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| Endo USA, Inc. | 1 | $21 |
| Urogen Pharma, Inc. | 1 | $20 |
| Civco Medical Instruments | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| Mayne Pharma Commercial LLC | 1 | $17 |
| Merck | 1 | $17 |
| Accord Healthcare, Inc. | 1 | $16 |
| Avation Medical, Inc. | 1 | $15 |
| Allegis Pharmaceuticals, LLC | 1 | $11 |
| Uc-care (USA), Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,771 in reported general payments places this provider in the 55th percentile of 878 urology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 105 | $59,815 |
| GemtesaVibegron | 76 | $52,046 |
| Bethanechol Chloride | 125 | $8,156 |
| NitrofurantoinNitrofurantoin Macrocrystal | 127 | $5,701 |
| Estradiol | 50 | $3,464 |
| Tamsulosin Hcl | 233 | $2,661 |
| Solifenacin Succinate | 83 | $2,200 |
| Testosterone Cypionate | 39 | $1,977 |
| Desmopressin Acetate | 35 | $774 |
| Finasteride | 70 | $714 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 56 | $518 |
| Fluconazole | 25 | $413 |
| Ciprofloxacin Hcl | 60 | $393 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 27 | $384 |
| Megestrol Acetate | 34 | $372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $243 | $59,815105 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $684 | $52,04676 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 878 urology providers in Texas.
Other urology in Waxahachie
- Zvi SchiffmanHouston$17.8M
- Jose de la CerdaSan Antonio$9M
- Daniel SaltzsteinSan Antonio$5.8M
- Jose KaramHouston$5.7M
- Daniel ZainfeldSan Antonio$4.7M
- Brian MazzarellaLakeway$4.5M
- Andrew von EschenbachMontgomery$3.2M
- Raj SatkunasivamHouston$2.6M
- Alan SkolnickHouston$2.4M
- Homa PorterDallas$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.